This study is exploring if adding a drug called durvalumab to chemotherapy helps patients with a type of cancer in the urinary tract before they have surgery. Durvalumab is an immunotherapy drug that helps the body's immune system fight cancer. Chemotherapy uses strong medicines to kill cancer cells or stop them from spreading. The study aims to see if the combination treatment works better than chemotherapy alone.

• The study lasts for several months, including treatment and follow-up visits every 3-6 months for up to 5 years.
• Participants will receive either chemotherapy alone or with durvalumab, followed by surgery.
• Various tests, like blood samples and scans, will be done throughout the study to monitor progress.

To join, you must be 18 or older, with specific medical criteria. You can't participate if you're pregnant, breastfeeding, or have certain other health issues. If you have questions or are interested, talk to your doctor about whether this study is right for you.